Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam and Isis Pen Alliance for RNAi Therapeutics

NEW YORK, March 12 (GenomeWeb News) - Isis Pharmaceuticals and Alnylam Pharmaceuticals will jointly develop and commercialize RNAi therapeutics, Isis said yesterday.

 

Under the agreement, Alnylam gains exclusive access to more than 150 of Isis' US patents for use in modifying double-stranded oligonucleotides. Alnylam's access also includes the "Crooke" patents, which cover fundamental mechanisms for Rnase-dependent antisense activity and chemically modified oligonucleotides. In addition, Isis will make a $10 million equity investment in Alnylam and give the company access to its manufacturing facilities and expertise for developing RNAi therapeutics. Moreover, Isis will pay Alnylam milestone fees and royalties on any RNAi-based drugs resulting from Alnylam's technologies.

 

In return, Cambridge, Mass.-based Alnylam will pay Isis a $5 million technology access fee, contribute to partnering fees, and make downstream milestone and royalty payments.

 

The companies will also share proceeds from licenses Alnylam grants under a previously announced program that include sublicenses to Isis' patents. Isis, based in Carlsbad, Calif., will retain certain rights to a number of targets for double-stranded RNAi drugs.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.